Iterum Therapeutics plc (ITRM)
Iterum Therapeutics Provides Business Update
Reviva Pharmaceuticals Holdings Inc. (RVPH)
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
Profound Medical Corp (PROF)
Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th
Coya Therapeutics Inc (COYA)
CoyaTherapeutics - Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Cooper Companies Inc (COO)
CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors
Lixte Biotechnology Holdings Inc. (LIXTW)
LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial
Cassava Sciences Inc. (SAVA)
Cassava Announces Agreement to Settle Securities Class Action Litigation
Reviva Pharmaceuticals Holdings Inc. (RVPHW)
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
Cassava Sciences Inc. (SAVAW)
Cassava Announces Agreement to Settle Securities Class Action Litigation
Trinity Biotech plc (TRIB)
Trinity Biotech Awarded a Major Order for 9 Million TrinScreen HIV Tests